PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight

A comprehensive analysis reveals over 180 companies developing 200+ PD-1 and PD-L1 inhibitor drugs across various clinical stages. The report highlights major pharmaceutical players advancing pipeline therapies for multiple cancer indications, with approximately 15+ drugs in late-stage development and 30+ in mid and early stages. Recent developments include FDA breakthrough designations and positive clinical trial results for combination therapies.

07/21/2026, 1:00 PM • GlobeNewswire

Antiparasitic Drugs Market Report Released — Examines Antimalarials, Anthelmintics, Antiprotozoals, Ectoparasiticides, and Neglected Tropical Disease Therapies

The global antiparasitic drugs market is projected to grow from USD 23.30 billion in 2026 to USD 30.98 billion by 2032 at a 4.88% CAGR. Growth is driven by persistent parasitic disease burden, drug resistance, climate-sensitive vector transmission, and public health programs. Key opportunities include resistance-ready combination therapies, pediatric formulations, AI-enabled discovery, and diagnostics-linked prescribing, with Africa and Asia-Pacific leading endemic demand.

07/20/2026, 11:52 AM • GlobeNewswire

American Kidney Fund Expands Kidney Health Coach Program with Educational Course on Lupus Nephritis

The American Kidney Fund (AKF) has launched an online educational course on lupus nephritis through its Kidney Health Coach program to educate healthcare professionals and community members about symptoms, testing, diagnosis, and treatment. The course, developed with subject matter experts, aims to empower over 8,000 volunteer Kidney Health Coaches across all 50 states. An estimated 1.5 million Americans have lupus, with about half developing lupus nephritis, which disproportionately affects women and racial/ethnic minorities.

07/16/2026, 10:39 AM • GlobeNewswire

Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider

The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

07/15/2026, 11:00 AM • GlobeNewswire

Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?

Moderna and Recursion Pharmaceuticals represent two distinct approaches to biotech innovation: Moderna leverages proven mRNA technology with diversifying pipeline into oncology and rare diseases, while Recursion uses AI-driven drug discovery. Despite both operating at losses, Moderna is favored for 2026 due to its established revenue base and proven formula, whereas Recursion remains in earlier development stages with revenue expected to decline due to lower milestone payments.

07/03/2026, 11:14 AM • The Motley Fool

Big Pharma Has a Case of Merger Mania

The pharmaceutical industry is experiencing a record-breaking M&A wave in 2026, driven by looming patent cliffs worth $300 billion in annual revenue, FDA regulatory improvements for rare diseases, and the need to diversify portfolios. Companies are making strategic bolt-on acquisitions of late-stage drug candidates rather than massive mergers. While some firms like Eli Lilly are well-positioned, others like Merck and Pfizer face near-term patent expirations that could impact revenue significantly.

06/30/2026, 12:26 AM • The Motley Fool

Global HPV Vaccines Market to Grow Rapidly at a CAGR of ~8% by 2034 | DelveInsight

The global HPV vaccines market is projected to grow from USD 8.9 billion in 2025 to USD 18.4 billion by 2034, driven by rising HPV-associated cancer prevalence, expanding government immunization programs, and advancements in multivalent vaccines. North America leads the market with 41% share, while Asia-Pacific emerges as a significant growth contributor. Key developments include Merck's presentation of long-term vaccine effectiveness data and China's approval of the first domestically-developed 9-valent HPV vaccine.

06/24/2026, 1:00 PM • GlobeNewswire

Sitryx Completes Enrollment in Phase 1b Trial of First-in-Class Oral PKM2 Modulator SYX-5219 in Atopic Dermatitis

Sitryx Therapeutics announced completion of enrollment in its Phase 1b clinical trial of SYX-5219, a first-in-class oral PKM2 modulator for moderate to severe atopic dermatitis, ahead of schedule. The trial enrolled 50 patients across US and European sites and is expected to readout in Q4 2026. The milestone follows positive Phase 1a data showing safety and immunomodulation of type 2 inflammation.

06/22/2026, 7:00 AM • GlobeNewswire

GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs

GSK and Spero Therapeutics announced FDA approval of Utebzi (tebipenem pivoxil hydrobromide), the first oral carbapenem antibiotic for treating complicated urinary tract infections including pyelonephritis. The drug demonstrated non-inferiority to intravenous imipenem-cilastatin in Phase 3 trials and is expected to launch in the U.S. by end of 2026, offering an alternative to hospital-based IV treatments for the 3+ million Americans annually affected by cUTIs.

06/17/2026, 1:29 PM • Benzinga

[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global GLP-1 receptor agonist market, valued at USD 28.7 billion in 2025, is projected to grow to USD 95.3 billion by 2035 at a 12.1% CAGR. Growth is driven by rising type 2 diabetes and obesity cases, technological innovations including oral formulations, and expanded insurance coverage. North America leads the market while Asia Pacific shows the highest growth rate.

06/16/2026, 6:30 PM • GlobeNewswire

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

GSK announced a $10.6 billion all-cash acquisition of Nuvalent at $124 per share, representing a 40% premium. The deal reflects Big Pharma's aggressive capital deployment to address an impending patent cliff, as GSK faces revenue loss from dolutegravir's expiring exclusivity. Nuvalent brings two late-stage kinase inhibitors targeting non-small cell lung cancer with FDA Breakthrough Therapy designations, triggering a short squeeze and signaling potential industry consolidation in oncology.

06/11/2026, 1:18 PM • Investing

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent

GSK agreed to acquire Nuvalent for $10.6 billion in cash, marking its largest acquisition in over a decade. The deal provides GSK with three lung cancer assets including lead drug candidates zidesamtinib and neladalkib for non-small cell lung cancer treatment. The acquisition is expected to contribute to revenue growth and be accretive to sales and core operating profit beginning in 2027.

06/09/2026, 6:52 AM • Benzinga

Lilly Just Announced 3 Infectious Disease Acquisitions in 1 Day. Is This the Beginning of Its Post-Obesity Growth Strategy?

Eli Lilly announced three infectious disease acquisitions in a single day—Curevo (shingles vaccine), LimmaTech Biologics (bacterial pathogen vaccines), and Vaccine Company (viral infection prevention)—totaling over $3.8 billion. These deals signal management's strategy to diversify beyond its blockbuster obesity drugs (Zepbound and Mounjaro) and build new growth engines focused on disease prevention, particularly addressing antimicrobial resistance and infections linked to serious conditions like multiple sclerosis and cancer.

06/08/2026, 5:23 PM • The Motley Fool

Tacrolimus Market Research Report 2026: Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2035

The global tacrolimus market is projected to grow from USD 7.3 billion in 2025 to USD 12.7 billion by 2035 at a CAGR of 5.6%, driven by rising organ transplant procedures and increasing autoimmune disease prevalence. Injectable formulations and hospital settings dominate the market, with North America accounting for 40.4% of the market share. Key players are investing in R&D for improved formulations and expanding into emerging markets.

05/25/2026, 5:31 AM • GlobeNewswire

Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Over 50 pharmaceutical companies are advancing 55+ pipeline drugs for pulmonary arterial hypertension (PAH) treatment. Recent developments include United Therapeutics' ralinepag meeting Phase III endpoints with 55% risk reduction, Gossamer Bio's seralutinib Phase III results, GSK's acquisition of 35Pharma for HS235, and Inhibikase Therapeutics enrolling patients in Phase III IMPROVE-PAH trial. Multiple novel mechanisms of action are being explored to address persistent clinical gaps in PAH management.

05/19/2026, 1:00 PM • GlobeNewswire